Anti-tumor necrosis factor therapy in Bulgarian pediatric patients with inflammatory bowel disease - an 8-year experience of a referral center.
| Autor: | Shentova-Eneva RR; Medical University of Sofia, Sofia, Bulgaria., Kofinova DR; Medical University of Sofia, Sofia, Bulgaria., Baycheva MZ; Medical University of Sofia, Sofia, Bulgaria., Hadzhiyski PG; Medical University of Sofia, Sofia, Bulgaria., Naydenov HB; Medical University of Sofia, Sofia, Bulgaria., Yaneva PG; Medical University of Sofia, Sofia, Bulgaria., Lazarova EA; Medical University of Sofia, Sofia, Bulgaria. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Folia medica [Folia Med (Plovdiv)] 2023 Aug 31; Vol. 65 (4), pp. 605-611. |
| DOI: | 10.3897/folmed.65.e84368 |
| Abstrakt: | Introduction: Anti-tumor necrosis factor (anti-TNF) therapy has become a mainstay in the treatment of patients with inflammatory bowel disease over the past few decades. (This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|